Login

FDA Aims To Speed Clinical Trials, Improve Device Safety Through Post-Market Evaluation, But Funding A Hurdle

FDA's device center chief Jeff Shuren, in an interview with Inside Health Policy , highlighted the benefit a robust National Device Evaluation System could have in bolstering the agency's ability to monitor devices in real-time to better inform the risk-benefit profile of approved products. Such a system, he said, could also help in the premarket approval phase to reduce the clinical trial burden on manufacturers and get products to market faster. The program is a high priority for the Center...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.